HC Wainwright Has Positive Forecast for CADL Q2 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL) – Equities research analysts at HC Wainwright raised their Q2 2026 earnings per share (EPS) estimates for Candel Therapeutics in a report issued on Friday, May 15th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.24) per share for the quarter, up from their previous forecast of ($0.27). The consensus estimate for Candel Therapeutics’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Candel Therapeutics’ Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at $0.35 EPS, FY2028 earnings at $0.71 EPS and FY2029 earnings at $1.45 EPS.

A number of other equities research analysts have also issued reports on CADL. Zacks Research upgraded Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Monday, April 20th. Cantor Fitzgerald assumed coverage on Candel Therapeutics in a research note on Monday, April 20th. They issued an “overweight” rating for the company. Citigroup lowered their target price on Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, March 13th. Finally, Wall Street Zen upgraded Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Candel Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Candel Therapeutics Stock Performance

Shares of NASDAQ:CADL opened at $7.90 on Tuesday. The firm has a market capitalization of $578.83 million, a PE ratio of -8.06 and a beta of -0.59. The company has a debt-to-equity ratio of 0.34, a current ratio of 28.05 and a quick ratio of 28.05. The business has a 50-day moving average of $5.97 and a two-hundred day moving average of $5.64. Candel Therapeutics has a 12 month low of $4.35 and a 12 month high of $9.27.

Candel Therapeutics (NASDAQ:CADL) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.16.

Insider Activity

In related news, Director Paul B. Manning bought 550,458 shares of the stock in a transaction dated Monday, February 23rd. The stock was acquired at an average price of $5.45 per share, for a total transaction of $2,999,996.10. Following the completion of the purchase, the director owned 2,763,527 shares in the company, valued at $15,061,222.15. This represents a 24.87% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 14.30% of the company’s stock.

Institutional Investors Weigh In On Candel Therapeutics

Hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its stake in Candel Therapeutics by 128.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock valued at $40,000 after purchasing an additional 4,439 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Candel Therapeutics during the 4th quarter valued at approximately $51,000. Tower Research Capital LLC TRC grew its stake in Candel Therapeutics by 361.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock valued at $49,000 after purchasing an additional 7,527 shares in the last quarter. Invesco Ltd. acquired a new stake in Candel Therapeutics during the 1st quarter valued at approximately $59,000. Finally, ProShare Advisors LLC acquired a new stake in Candel Therapeutics during the 4th quarter valued at approximately $59,000. Institutional investors and hedge funds own 13.93% of the company’s stock.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.